France
2.3researchedCommercially the most exciting continental market, any doctor has been able to prescribe since June 2025 and reimbursement arrived in June 2026, and by a distance the most aggressively policed: ANSM fined Novo Nordisk €1.78m and Eli Lilly €108,766 in April 2026 for obesity-awareness campaigns it read as indirect advertising.
- Population
- 68m
- Currency
- EUR
- Region
- Western Europe
- Updated
- 2026-08-23
The six axes
Five is always better for an operator. Hover a label for the question it answers.
How it works here
Ownership [1]
Absolute. Under Code de la santé publique art. R5125-19, nobody exercising a health profession other than community pharmacy, and no non-pharmacist, may hold shares in the société d'exercice libéral operating a pharmacy. A pharmacist may hold interests in at most two additional pharmacy companies beyond the one they practise in (art. R5125-18).
A foreign founder can wholly own the telehealth and technology entity. Only the dispensing leg is closed.
Prescribing opened up in June 2025 [1][2]
Until 23 June 2025, initiating Wegovy, Saxenda or Mounjaro for obesity required an endocrinology or nutrition specialist. ANSM then extended initiation and renewal to any physician, citing access delays and territorial inequality. The products remain prescription-only, second-line after failed nutritional management, and ANSM warns explicitly against cosmetic use.
No video-consultation mandate appears in ANSM's own text, and questionnaire-based teleconsultation appears to operate in practice, though ZAVA's French pages state plainly that Wegovy "ne peut pas être acheté en ligne", since the prescription must be filled in person at a pharmacy.
Reimbursement from 15 June 2026 [1][2]
Wegovy and Mounjaro became reimbursed at 65% in ambulatory care for adults with BMI ≥40, or ≥35 with a qualifying comorbidity, after documented failure of nutritional management (<5% weight loss at six months). Initial reimbursed prescriptions are restricted to physicians in specialised obesity-care settings, university hospitals, or obesity-centre-linked endocrinologists; any physician may renew.
List prices: Wegovy €146.91 (0.25–1mg), €169.31 (1.7mg), €195.10 (2.4mg) per pen. Mounjaro €176.10 (2.5mg), €237.68 (5mg), €335.95 (7.5–10mg), €433.80 (12.5–15mg). The health minister estimated a full-year cost around €100m for roughly one million eligible patients.
France's negotiated price matters beyond France: it feeds the external reference pricing used across much of Europe.
Enforcement [1][2][3]
On 29 April 2026 ANSM issued financial sanctions of €1,783,838.20 against Novo Nordisk (€1,000,000 for Saxenda, €783,838.20 for Wegovy) and €108,766.50 against Eli Lilly France for obesity disease-awareness campaigns judged to constitute indirect advertising of prescription-only medicines to the public. If the manufacturers are being fined seven figures for awareness marketing, a brand has no room at all.
Separately ANSM has referred cases to prosecutors under Art. 40 CPP, filed around 20 Pharos reports against roughly 10 merchant sites, opened police sanitaire proceedings against about 10 online platforms, and begun lab analysis of counterfeit GLP-1 "patches".
Who is already there
| Name | Model | Price |
|---|---|---|
| Qare | French telehealth platform, secure video and async consultation; patient fills at any pharmacy | n/a |
| ZAVA France | Questionnaire-based, no live video; does not dispense, the patient fills the prescription at an ordinary pharmacy | €28 consultation fee |
| Annette | Structured multidisciplinary obesity care, app, dietitians, psychologists, physicians. €2m seed December 2025 (Redstone, Ring Capital, AFI Ventures, Clover VC, Gfund); claims >1,000 patients and 90% three-month retention | n/a |
| DoktorABC | Pan-European platform active in France since 2022, using doctors licensed in Germany and Norway rather than France, described in French trade press as contested territory | €29.90 consultation |
Routes in, and walls
What works viable
- Build the telehealth prescribing layer, physician panel plus software, and let patients fill at any French pharmacy. No pharmacy ownership required.
- Target the population outside the reimbursement criteria: BMI under 35, or unable to reach a specialist to initiate.
What does not blocked
- Owning or controlling a pharmacy or its operating SEL as a non-pharmacist. Absolute.
- Consumer-facing "obesity awareness" marketing tied to a branded product. ANSM fined the manufacturers for exactly this.
- Rx mail order, domestic or inbound.
- Relying on a non-French-licensed prescriber model without serious local legal comfort.
How to make it work
The recommended entry path for a non-pharmacist operator running an own brand with a partner pharmacy. Read it against the six axes above, not instead of them.
Build the prescribing layer and physician panel, let patients fill at any pharmacy, and target the population outside the reimbursement criteria.
No pharmacy ownership is available and mail order is heavily restricted. What France does have is a large population outside the reimbursement gate, BMI under 35 or unable to reach a specialist to initiate, and that is a genuine self-pay market. But you will only ever hold the software and the doctors.
- Build the physician panel and the platformNo pharmacy ownership is required because none is available.
- Target the sub-35 BMI and specialist-access-blocked populationThat is where the self-pay demand concentrates.
- Read the advertising rules before spendingFrance scores 1 out of 5 on advertising room.
Reimbursement policy could move the addressable market underneath you in either direction, and you have no structural position to defend.
Low capital, thin margin.
What has happened
What we could not establish
Kept visible on purpose. These are the gaps a decision would have to close.
- What article numbers did ANSM rely on in the April 2026 sanction decision? The ANSM decision page 404s.
- Is a formulaire or attestation now mandatory at dispensing for private, non-reimbursed GLP-1 prescriptions, or only for the reimbursement pathway?
- Has HAS issued a formal reimbursement opinion on Rybelsus? Only secondary reporting was found.
On the shared backlog: Are France, Belgium and Ireland definitively closed to inbound Rx mail order?
Sources
Every non-obvious claim above links here. Confidence tags are applied strictly.
Read next
The advertising wall
Every EU state bans advertising prescription medicines to the public. What differs is how far "advertising" reaches, and how hard anyone is looking.
topicWho can own a pharmacy
The single structural fact that decides whether you can own the margin or only rent it, and it varies more across Europe than anything else in this atlas.
topicGetting stock
The manufacturers have taken control of distribution, and that is now a bigger constraint on a new entrant than any regulator.
topicZava
DrEd’s original regulatory arbitrage, rebuilt through Dublin after Brexit and now sitting inside a NYSE-listed issuer alongside its own opposite number.
companyHims & Hers
The US-listed telehealth company that, through two acquisitions, became the dominant single owner of European DTC weight-loss brands.
companyRedcare Pharmacy
The pharmacy that lost the Zava case, and is running the Zava referral again today from its own product pages.
companyDocMorris
A pharmacy that owns its own prescriber, which is the exact structure §11 ApoG exists to prevent, and it lost on that point in April 2026.
companyDoktorABC
Germany’s largest GLP-1 seller by review volume, and a one-pound UK web-portal company that has never been sued by anyone anywhere.
company